(Ferrocenylpyrazolyl) zinc (II) benzoates as catalysts for the ring opening polymerization of ε-caprolactone

The reaction of Zn(OAc)2 and C6H5COOH or 3,5-NO2-C6H3COOH with 3-ferrocenylpyrazolyl-methylenepyridine (L1), 3-ferrocenyl-5-methylpyrazolyl-methylenepyridine (L2), 3-ferrocenylpyrazolyl-ethylamine (L3) and 3-ferrocenyl-5-pyrazolyl-ethylamine (L4) afford the corresponding complexes [Zn(C6H5COO)2(L1)] (1), [Zn(C6H5COO)2(L2)] (2), [Zn(3,5-NO2-C6H3COO)2(L1)] (3), [Zn(3,5-NO2-C6H3 COO)2(L2)] (4), [Zn(C6H5COO)2(L3)] (5), [Zn(C6H5COO)2(L4)] (6), [Zn(3,5-NO2-C6H3COO)2(L3)] (7) and [Zn(3,5-NO2-C6H3COO)2(L4)] (8). These complexes behave as catalysts for the ring opening polymerization of e-caprolactone to produce polymers with molecular weight that range from 1480 to 7080 g mol1 and exhibited moderate to broad PDIs. Evidence of these complexes acting as catalysts was obtained from both the polymerization data and kinetic studies. The polymerization data show that variation of the [CL]/[C] from 100 to 800 produced PCL with relatively the same molecular weight indicative of a catalyst behavior. The appearance of induction period in kinetic plots strengthens the fact that these complexes are catalysts rather than initiators. MALDI-TOF MS and 1 H NMR data show di-hydroxy end groups, which support the coordination mechanism rather than insertion mechanism. To understand the broad PDIs obtained for some of the polymer, the electronic properties of the zinc complexes were investigated using cyclic voltammetry. The results show that the zinc complexes containing amine based ligands are highly electrophilic therefore making them unstable, hence the broad PDIs observed for zinc complexes containing amine based ligands. Among the eight complexes investigated, complex 7 is the most active catalyst with kp value of 1.18 107 h1 mol1 at 110 C

Catalysis of linear alkene metathesis by Grubbs-type ruthenium alkylidene complexes containing hemilabile α,α-diphenyl-(monosubstituted-pyridin-2-yl)methanolato ligands

Four new Grubbs-type precatalysts [RuCl(H2IMes)(O^N)(=CHPh)], where [O^N = α,α-diphenyl-(3-methylpyridin-2-yl)methanolato, α,α-diphenyl-(4-methylpyridin-2-yl)methanolato, α,α-diphenyl-(5-methylpyridin-2-yl)methanolato and α,α-diphenyl-(3-methoxypyridin-2-yl)methanolato] were synthesized and tested for their activity, stability and selectivity in the 1-octene metathesis reaction. Overall the precatalysts showed good activity and high stability for the metathesis of 1-octene at temperatures above 80 °C and up to 110 °C. Selectivities towards the primary metathesis products, i.e., 7-tetradecene and ethene, above 85% were obtained with all the precatalysts at 80 and 90 °C. High selectivities were also observed at 100 °C for the 4-Me- and 3-OMe-substituted precatalysts. With an increase in temperature an increase in isomerisation products and secondary metathesis products were observed with the latter reaching values >20% for the 3-OMe- and 3-Me-substituted precatalysts at 110 and 100 °C, respectively. All the precatalysts exhibits first-order kinetics at 80 °C with the 3-substituted precatalysts the slowest. The behaviour of the 3-substituted precatalysts can be attributed to electronic and steric effects associated with the adjacent bulky phenyl groups

Analysis of reaction mixtures of perhydro-dibenzyltoluene using two-dimensional gas chromatography and single quadrupole gas chromatography

Energy storage via liquid organic hydrogen carrier (LOHC) systems has gained significant attention in recent times. A dibenzyltoluene (DBT) based LOHC offers excellent properties which largely solve today's hydrogen storage challenges. Understanding the course of the dehydrogenation reaction is important for catalyst and process optimization. Therefore, reliable and exact methods to determine the degree of hydrogenation (doh) are important. We here present other possible techniques, namely: comprehensive two-dimensional gas chromatography coupled with time of flight mass spectrometry (2D-GC-TOF-MS) and single quadrupole-mass spectrometry gas chromatogram system (GC-SQ-MS). The 2D-GC-TOF-MS results indicate that isomer fractions lose three molecules of hydrogen, as follows: H18-DBT, H12-DBT, H6-DBT and H0-DBT, and the doh decreases with an increase in dehydrogenation temperature. 1H NMR and GC-SQ-MS were employed as additional analytical techniques. The GC-SQ-MS was also used to analyse decomposition products that result from thermal cracking of reaction mixture molecules

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Aim To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin® SC, H SC), delivered from an H SC Vial via hand-held syringe (Cohort A) or single-use injection device (Cohort B), with or without chemotherapy, for human epidermal growth factor receptor 2 (HER2)-positive stage I to IIIC early breast cancer (EBC) in the phase III SafeHer study (NCT01566721). Methods Patients received 600 mg fixed-dose H SC every 3 weeks for 18 cycles. The chemotherapy partner was at the investigators' discretion (H SC monotherapy was limited to ≤10% of the population). Data from the first H SC dose until 28 days (plus a 5-day window) after the last dose are presented. Results are descriptive. Results In the overall population, 2282/2573 patients (88.7%) experienced adverse events (AEs). Of the above, 128 (5.0%) patients experienced AEs leading to study drug discontinuation; 596 (23.2%) experienced grade ≥ 3 AEs and 326 (12.7%) experienced serious AEs. Grade ≥ 3 cardiac disorders were reported in 24 patients (0.9%), including congestive heart failure in eight (0.3%). As expected, the AE rates varied according to the timing of chemotherapy in both cohorts, with higher rates in concurrent versus sequential chemotherapy subgroups. In the concurrent chemotherapy subgroup, AEs were more common during the actual period of concurrent chemotherapy compared with the period when patients did not receive concurrent chemotherapy. Conclusion SafeHer confirms the safety and tolerability of the H SC 600 mg fixed dose for 1 year (every 3 weeks for 18 cycles) as adjuvant therapy with concurrent or sequential chemotherapy for HER2-positive EBC. These primary analysis results are consistent with the known safety profile for intravenous H and H SC